Obstructive Sleep Apnoea and Hypertension: GLP-1 Receptor Agonists as Emerging Therapy
Afzal M, Livesey A, Hameed MA, Mukherjee R
Summary
This review of obstructive sleep apnoea-related hypertension highlights GLP-1 receptor agonists as a promising emerging therapy alongside endothelin receptor antagonists. The authors note that GLP-1 RAs may address multiple pathophysiological mechanisms in OSA-related hypertension, including sympathetic overactivity and endothelial dysfunction, though further trials are needed.
Clinical Significance
Expands the potential therapeutic footprint of GLP-1 RAs beyond diabetes and obesity into sleep medicine and resistant hypertension. OSA affects 30-50% of hypertensive patients, and GLP-1 RAs could offer dual benefit through weight reduction and direct cardiovascular effects.
Cercetări conexe
Determinants of VO2peak Responsiveness to Aerobic Exercise Training in Adults with Type 2 Diabetes: The PROTECTION Study
In 108 adults with Type 2 diabetes participating in a 26-week supervised cycling programme, GLP-1 re…
Association of Dual SGLT-2 Inhibitor and GLP-1 Receptor Agonist Therapy with Colon Cancer Risk in Post-Polypectomy Patients with Diabetes: A Target Trial Emulation
This target trial emulation study examined whether dual SGLT-2 inhibitor and GLP-1 receptor agonist …
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis evaluated the association between GLP-1 receptor agonist use and de…
GLP-1 Receptor Agonist Therapy in Adults With Sickle Cell Disease and Type 2 Diabetes: A Real-World Cohort Analysis
This real-world study of 1,391 matched patients with sickle cell disease (SCD) and type 2 diabetes f…